Idera Pharmaceuticals Inc. (IDRA) announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection or HCV.
IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.
The company said that, in this 4-week trial, IMO-2125 was well tolerated and induced dose-dependent increases in endogenous interferon-alpha and other cytokines. Also, IMO-2125 demonstrated a treatment-related decrease in viral load at escalating dose levels.
Based on these data, the company noted that it is extending the trial to a fifth dose level and beginning to recruit patients in this cohort. Idera Pharma intends to use the ongoing clinical trial results to guide its strategy for further development of IMO-2125 for the null responder HCV patient population.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.